Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9869778 | 0.88 | KEAP1 (0.48) | ALDH1A1KDM4EKEAP1SMN1; SMN2TSHR | |
| SCHEMBL1998371 | 0.80 | HRH3 (0.39) | ALDH1A1TDP1KMT2AMEN1 | |
| SCHEMBL15660677 | 0.78 | KDM4E (0.39) | GLAALDH1A1KDM4EKEAP1SMN1; SMN2 | |
| SCHEMBL7706424 | 0.78 | HRH3 (0.42) | ALDH1A1KDM4ESMN1; SMN2NPC1TSHR | |
| SCHEMBL5946046 | 0.77 | ALDH1A1 (0.37) | ALDH1A1KDM4ENPC1RAB9AKMT2A | |
| SCHEMBL14538844 | 0.76 | KDM4E (0.46) | GLAALDH1A1KDM4EKEAP1SMN1; SMN2 | |
| SCHEMBL9534058 | 0.75 | KDM1A (0.32) | — | |
| SCHEMBL5540209 | 0.75 | POLB (0.45) | ALDH1A1KDM4ESMN1; SMN2TDP1KMT2A | |
| SCHEMBL111438 | 0.75 | TSHR (0.58) | GLAALDH1A1KDM4EKEAP1SMN1; SMN2 | |
| SCHEMBL235080 | 0.74 | KDM4E (0.65) | GLAALDH1A1KDM4EKEAP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283357-B2 | Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-10-09 | — | — | US | claimed |
| EP-2440517-A2 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-04-18 | — | — | EP | claimed |
| EP-2427447-A2 | SMALL MOLECULE INHIBITORS OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION | Pike Pharma GmbH (CH) | 2012-03-14 | — | — | EP | claimed |
| US-7855292-B2 | Cholecystokinin (CCK) receptor ligands; antagonists; 3-(5-Bromo-thiophen-2-yl)-2-[4-chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-propionic acid methy; pain, drug dependence, anxiety, panic attack, schizophrenia, pancreatic disorders, secretory disorders, ulcers, cancers; improved pharmacokinetics | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-21 | — | — | US | claimed |
| WO-2010144378-A2 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD COLORADO, INC. (US) | 2010-12-16 | — | — | WO | claimed |
| US-20100311794-A1 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-12-09 | — | — | US | claimed |
| US-20100292240-A1 | SULFONAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | claimed |
| WO-2010128163-A2 | SMALL MOLECULE INHIBITORS OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION | PIKE PHARMA GMBH (CH) | 2010-11-11 | — | — | WO | claimed |
| US-20080132511-A1 | Cholecystokinin (CCK) receptor ligands; antagonists; 3-(5-Bromo-thiophen-2-yl)-2-[4-chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-propionic acid methy; pain, drug dependence, anxiety, panic attack, schizophrenia, pancreatic disorders, secretory disorders, ulcers, cancers; improved pharmacokinetics | JANSSEN PHARMACEUTICA NV (BE) | 2008-06-05 | — | — | US | claimed |
| US-7297816-B2 | Sulfonamide compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-20 | — | — | US | claimed |
| EP-1797083-A1 | SULFONAMIDE COMPOUNDS | Janssen Pharmaceutica, N.V. (BE) | 2007-06-20 | — | — | EP | claimed |
| WO-2006036670-A1 | SULFONAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-04-06 | — | — | WO | claimed |
| US-20060069286-A1 | Sulfonamide compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-03-30 | — | — | US | claimed |
| EP-3452465-B1 | SUBSTITUTED 2, 4-DIAMINO-QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | GENOSCIENCE PHARMA (FR) | 2020-11-04 | — | — | EP | disclosed |
| US-10577362-B2 | Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases | GENOSCIENCE PHARMA (FR) | 2020-03-03 | — | — | US | disclosed |
| US-20190144437-A1 | SUBSTITUTED 2, 4-DIAMINO-QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | GENOSCIENCE PHARMA (FR) | 2019-05-16 | — | — | US | disclosed |
| EP-0111453-A1 | Amide derivatives | CIBA-GEIGY AG (CH) | 1984-06-20 | — | — | EP | disclosed |
| EP-0111455-A2 | Unsaturated lactones | CIBA-GEIGY AG (CH) | 1984-06-20 | — | — | EP | disclosed |
| EP-0089926-A2 | Pharmaceutical preparations of tetracycles containing nitrogen, and compounds of this type | CIBA-GEIGY AG (CH) | 1983-09-28 | — | — | EP | disclosed |
| EP-0083315-A2 | Pyridyl-N-oxides, processes for their preparation and pharmaceutical compositions containing them | CIBA-GEIGY AG (CH) | 1983-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132511-A1 | Cholecystokinin (CCK) receptor ligands; antagonists; 3-(5-Bromo-thiophen-2-yl)-2-[4-chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-propionic acid methy; pain, drug dependence, anxiety, panic attack, schizophrenia, pancreatic disorders, secretory disorders, ulcers, cancers; improved pharmacokinetics | CCKAR, CCKBR, GRPR | GLA 4611/4885ALDH1A1 1954/4885KDM4E 4720/4885 |
| US-20190144437-A1 | SUBSTITUTED 2, 4-DIAMINO-QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | NQO2, RECQL, CCNO | GLA 1215/4885ALDH1A1 334/4885KDM4E 2623/4885 |
| US-20100292240-A1 | SULFONAMIDE COMPOUNDS | CCKAR, CCKBR, TAS1R2 | GLA 4675/4885ALDH1A1 2749/4885KDM4E 3780/4885 |
| US-20100311794-A1 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | HDAC1, HDAC5, HDAC3 | GLA 569/4885ALDH1A1 739/4885KDM4E 135/4885 |
| US-10577362-B2 | Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases | NQO2, RECQL, CCNO | GLA 1215/4885ALDH1A1 334/4885KDM4E 2623/4885 |
| US-20060069286-A1 | Sulfonamide compounds | CCKAR, CCKBR, TAS1R2 | GLA 4675/4885ALDH1A1 2749/4885KDM4E 3780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.